Baxter(US:BAX) Globenewswire·2025-11-24 20:02Core Viewpoint - Baxter International, Inc. is facing a class action lawsuit due to allegations of issuing false and misleading statements regarding the safety and efficacy of its Novum LVP product, which reportedly has systemic defects leading to serious patient risks [3][4]. Group 1: Allegations and Issues - The complaint alleges that Baxter's Novum LVP product suffered from systemic defects causing malfunctions such as underinfusion, overinfusion, and complete non-delivery of fluids, exposing patients to serious injury or death [3]. - Baxter was reportedly notified of multiple device malfunctions, injuries, and deaths related to these defects, indicating a significant risk to patient safety [3]. - The company's attempts to address these defects through customer alerts were deemed inadequate, as design flaws persisted and continued to harm patients [3]. Group 2: Impact on Business Operations - Due to the defects, there is a heightened risk that customers may be instructed to take existing Novum LVPs out of service, and Baxter may need to pause all new sales of these pumps [3]. - Baxter's statements regarding the safety, efficacy, product rollout, customer feedback, and sales prospects of the Novum LVPs were found to be materially false and misleading, potentially impacting investor confidence and stock performance [3]. Group 3: Legal Proceedings and Shareholder Actions - Shareholders who purchased shares of Baxter during the class period from February 23, 2022, to July 30, 2025, are encouraged to register for the class action lawsuit, with a deadline for lead plaintiff appointment set for December 15, 2025 [4]. - Once registered, shareholders will be enrolled in a portfolio monitoring software to receive updates throughout the lifecycle of the case, indicating a structured approach to managing the legal proceedings [4].